Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Macrolide immunosuppressants.

U Mrowietz1

  • 1Department of Dermatology, University of Kiel, Schittenhelmstr. 7, 24105 Kiel, Germany. umrowietz@dermatology.uni-kiel.de

European Journal of Dermatology : EJD
|July 27, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[On the occasion of Professor Enno Christophers's 90th birthday].

Dermatologie (Heidelberg, Germany)·2026
Same author

Depression, a major comorbidity of psoriatic disease, is caused by metabolic inflammation.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Measuring well-being in psoriasis: psychometric properties of the WHO-5 questionnaire.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

EczemaPartner - adapting a questionnaire to assess the impact of atopic dermatitis on partners of patients.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same journal

Erratum.

European journal of dermatology : EJD·2026
Same journal

sQUIZ your knowledge! A hidden flexural pattern revealed.

European journal of dermatology : EJD·2026
Same journal

sQuiz your knowledge! A new pigmented lesion on the back of a young woman.

European journal of dermatology : EJD·2026
Same journal

sQuiz your knowledge! Multiple yellowish papules in an adult.

European journal of dermatology : EJD·2026
Same journal

sQuiz your knowledge! When plaques turn into tumours.

European journal of dermatology : EJD·2026
Same journal

sQuiz your knowledge! A gradually progressive pigmented dermatosis.

European journal of dermatology : EJD·2026
See all related articles

Macrolide immunosuppressants, including tacrolimus, show potent immunosuppressive effects for transplant rejection and dermatological conditions like atopic dermatitis. Their topical application is effective, with new macrolide compounds in development.

Area of Science:

  • Immunology
  • Pharmacology
  • Dermatology

Background:

  • Macrolide immunosuppressants are a novel class of compounds with significant immunosuppressive properties.
  • Tacrolimus is a well-established macrolide used for preventing transplant rejection.
  • The pharmaceutical industry is actively developing new macrolide immunosuppressants.

Purpose of the Study:

  • To review the pharmacological aspects of macrolide immunosuppressants.
  • To discuss their proposed mechanisms of action.
  • To summarize pre-clinical and clinical findings.

Main Methods:

  • Review of pharmacological data.
  • Analysis of in vitro and in vivo studies.
  • Evaluation of clinical trial results for topical applications.

Related Experiment Videos

Main Results:

  • Macrolide immunosuppressants exhibit potent immunosuppressive activity.
  • Topical formulations, such as tacrolimus and SDZ ASM 981, are effective for atopic dermatitis.
  • These compounds are suitable for topical treatment due to their chemical structure.

Conclusions:

  • Macrolide immunosuppressants represent a promising therapeutic class.
  • Their efficacy in dermatological disorders, particularly atopic dermatitis, is well-documented.
  • Ongoing research suggests a growing pipeline of macrolide-based therapies.